CFMG & Wellpath in California — a documentary investigation · Article 026 of 100 · Series 3 — Physician executives, ownership and succession

Dheeraj Taranath and the Enterprise Clinical Layer

Published

20 September 2026, 6:00 PM PT

Content last changed

20 September 2026, 6:00 PM PT

Public-evidence cutoff

20 September 2026, 6:00 PM PT

Sources checked

20 September 2026, 6:00 PM PT

Record through

20 September 2026, 6:00 PM PT

Editorial status

Public-source editorial review complete

Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.

Opening frame#

Dheeraj Taranath and the Enterprise Clinical Layer is a governance inquiry, not a title-matching exercise. Corporate office, medical leadership, stock ownership, enterprise employment, and practical decision authority are treated as distinct evidentiary categories. The record is strongest where those categories converge in executed documents and weakest where succession or ownership instruments remain unavailable.

The governing question is narrow: What is the difference between Wellpath's Chief Clinical Officer and CFMG's professional-corporation authority? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

I. The Question and the Public Record#

The relevant public record is best read cumulatively. No single branding statement, county agenda item, corporate filing, bankruptcy disclosure, or management agreement resolves the entire relationship. The evidentiary value comes from comparing documents created for different purposes and asking whether they converge on the same allocation of identity, authority, economics, and professional responsibility.

Raymond herr — the longest documented post-founder president#

The public record supports a strong chronology for Herr:

• April 2015 — identified in Shepherd evidence as CFMG Chief Medical Officer and President.

• March 2017 — signs CFMG collective-bargaining agreement as President.

• December 2017 — signs Stanislaus contract as President.

• 2018 — identified by Alameda County as CFMG Chief Medical Officer and President.

• September 2018 — CDPH lists him as President and Chief Medical Officer.

• 2018 — signs Fresno CFMG agreement as President.

• 2020 — appears on Placer agreement as CFMG President.

• September 8, 2021 — signs Monterey Amendment No. 2 as CFMG President.

This is a substantial run of formal corporate/contractual evidence.

It gives Herr an unusually important place in the governance history because his tenure spans:

• the mature H.I.G./CMGC period;

• the 2018 CCS–CMGC combination;

• the creation of the Wellpath brand;

• the 2019 MSA assignment to Wellpath LLC.

The key unanswered question is:

What happened to the CFMG shareholder, board, and Company Designee structure during the 2018–2019 Wellpath transition while Herr was president?

The public governance record actually contains strong defense evidence#

An objective CPOM record must recognize that the governance history contains evidence supporting the legality of the structure.

• CFMG consistently existed as a separate California professional corporation.

• Physician presidents signed major county agreements.

• Current directors are physicians.

• CFMG remained a nondebtor PC during Wellpath bankruptcy.

• Post-bankruptcy contracts continue to be signed in CFMG's name.

• Wellpath publicly says CFMG is physician-owned.

• Hallman publicly said there was no ownership overlap.

• County contracts invoke ordinary corporate-signature formalities.

• The current Secretary of State filing names physician directors rather than Wellpath's nonphysician executive board.

These facts weigh against a simplistic "shell company" narrative.

Corporate disclosures — affiliate/parent labels as source-tracing material#

Several federal cases include corporate-disclosure entries describing CFMG and Wellpath through “affiliate,” “other affiliate,” or more expansive relationship labels.

These are useful for establishing that a disclosed corporate relationship existed or was represented.

They are poor substitutes for:

• stock ledgers;

• shareholder agreements;

• capitalization tables;

• governance instruments;

• or the MSA.

A Rule 7.1 label should therefore be coded:

relationship representation — authenticate underlying corporate basis.

Exact disclosure language is reproduced here only with:

• case;

• ECF number;

• filing date;

• filing party;

• signatory;

• and surrounding form context.

II. Structural and Historical Context#

Records that would resolve the question#

• Actual Rule 7.1 / interested-entity PDFs from Beckner , Sand , Avila , Strieter , and post-bankruptcy CFMG cases.

• Every Overfield exhibit concerning Chapman termination.

• Chapman’s continued deposition once filed.

• Any renewed Hole deposition.

• Complete Smith same-entity stipulation and financial discovery record.

• Complete D.M. discovery correspondence supporting the same-functions representation.

• Complete Andrew Ho bankruptcy/arbitration references; public filings only.

• Napa Agreement 190201B and every amendment.

• County-by-county executed agreements and RFP proposals.

• CFMG/Wellpath quality-review policies implicated by Kartchner .

• Bankruptcy insurance/indemnity schedules naming CFMG.

• The 2012 MSA exhibits and every later amendment.

• All stock-transfer restriction / succession instruments referenced by the 2019 assignment.

• CFMG bylaws and shareholder/officer history.

• Physician employment templates pre-2018 vs post-2018.

• Wellpath enterprise clinical-policy approval matrices for California.

Shareholder-succession event table to build once the agreement is found#

For every historical owner transfer:

The likely historical periods needing reconstruction are:

• founder era;

• 2012–2013 H.I.G. transaction;

• Fithian/Herr transition;

• 2018 CCS–CMGC combination;

• Herr/Bazzel transition;

• 2024 bankruptcy;

• 2025 lender emergence;

• 2026 Local Government–California restructuring.

The chronology should remain blank where ownership is unproven rather than inferring ownership from officer titles.

III. The Control and Governance Analysis#

Documents with the highest evidentiary value#

the investigation should prioritize obtaining and authenticating:

• complete December 31, 2012 MSA;

• all amendments and restatements;

• 2019 assignment documents;

• stock-transfer restriction agreements;

• shareholder succession / replacement agreements;

• CFMG articles, bylaws, shareholder agreements, and board minutes;

• complete list of CFMG shareholders/directors/officers by year;

• “Company Designee” appointments;

• Wellpath/CFMG delegation-of-authority matrices;

• physician hiring and termination workflows;

• physician compensation approval matrices;

• HRIS and payroll audit trails;

• EHR ownership and administrator records;

• clinical policy approval metadata;

• county RFP responses describing management hierarchy;

• malpractice/GL coverage and indemnity instruments;

• outside-counsel retention/claims administration protocols;

• quality assurance and mortality-review governance documents;

• management-fee and intercompany accounting records;

• post-bankruptcy amendments or succession instruments.

Domain five — clinical policy and national vertical medical leadership#

A national Wellpath physician executive is still a physician. The fact that a clinical leader sits in Tennessee rather than California does not itself create a CPOM problem.

The questions are California licensure, CFMG authority, entity capacity, delegation, and final approval.

In April 2025, Wellpath’s Chief Medical Officer stated in writing that Wellpath was the Management Services Organization contracted to provide the full range of administrative services to CFMG . The same communication said Wellpath had reviewed disputed matters with CFMG leadership and was communicating with the CFMG physician with CFMG leadership’s knowledge and approval.

That evidence supports both sides:

Integration: a national Wellpath chief medical executive functioned as a central interface in a CFMG physician matter.

Potential independence/agency: he expressly represented that Wellpath was acting with CFMG leadership’s knowledge and approval.

Neither statement establishes whether CFMG approval was independent, contemporaneous, and meaningful.

For every enterprise clinical policy, the record should identify:

• who authored it;

• entity employing author;

• California licensure;

• who approved it for CFMG;

• whether CFMG-specific approval exists;

• whether CFMG could reject or modify it;

• whether CFMG ever did so;

• whether treating physicians could depart when clinically necessary.

Current assessment: National Wellpath clinical-leadership involvement is strong; CFMG’s contractual ultimate authority is strong; approval matrices and override evidence are missing.

Strongest evidence justifying further control investigation#

Conversely, several facts justify deeper investigation:

• The MSO is CFMG’s exclusive management-services provider.

• A management representative can attend and participate in CFMG equityholder/governance meetings, though without vote.

• CFMG physician employment forms are prepared by management and cannot be amended without management approval.

• The MSA assigns extensive physician HR functions to management.

• The MSA says management will determine physician base and incentive compensation .

• Management participates in staffing deliberations and schedule review.

• Wellpath publicly says it provides CFMG utilization-management functions.

• Management administers EMR systems and supervises storage/maintenance of patient records.

• Management negotiates client agreements and professional-service agreements on CFMG’s behalf.

• Management acquires/holds title to substantial equipment and recommends medical equipment.

• CFMG designated a Wellpath HR executive as Rule 30(b)(6) PMK about a CFMG physician termination.

• That witness testified the physician was terminated by management working for Wellpath.

• The Wellpath enterprise handbook is broad enough on its face to include entities managed by Wellpath LLC, while its exact application to CFMG physicians remains unresolved.

• Contemporaneous California operating records show Wellpath HR, clinical leadership, insurance, claims, and enterprise systems interacting directly with CFMG physician matters.

• The 2019 assignment transferred the MSA together with related stock-transfer restriction agreements into the Wellpath structure.

These facts do not establish illegality. They establish why approval and override evidence is essential.

Why these documents matter now#

California Attorney General enforcement in 2026 has focused directly on structures in which an MSO or private-equity-backed enterprise can:

• replace a physician shareholder;

• control who succeeds the shareholder;

• make physician ownership dependent on continued use of the MSO;

• prevent the physician practice from replacing the MSO without risking ownership.

That is precisely why the CFMG stock-transfer documents can no longer be treated as incidental corporate paperwork.

The decisive questions are:

• Who could become a CFMG shareholder?

• Who nominated or approved successors?

• Could Wellpath veto a proposed physician shareholder?

• Could Wellpath require replacement of a physician shareholder?

• What happened upon death, disability, loss of licensure, resignation, retirement, termination, or bankruptcy?

• Was any stock held in escrow?

• Did any proxy, option, nominee arrangement, succession list, or power of attorney exist?

• Who fixed the share-purchase price?

• Who funded the purchase?

• Did Wellpath or an affiliate possess a security interest tied to the shares?

• Could a physician owner remain owner after terminating the MSA?

• Could the physician owner sell to another qualified physician without Wellpath approval?

Until these instruments are obtained, no confident conclusion should be made about ultimate ownership succession.

Cfmg's nondebtor status does not mean economic independence#

The bankruptcy makes an important analytical distinction possible.

CFMG was not simply a Wellpath debtor affiliate.

But Wellpath sought court authority to:

• honor obligations to professional corporations;

• continue professional-corporation contractual relationships;

• pay obligations processed under those relationships;

• obtain new professional-corporation contracts.

Wellpath argued that uninterrupted performance under PC management agreements was necessary to preserve the value of its business.

That is evidence of reciprocal operational dependence.

The professional corporations needed management infrastructure.

The Wellpath business needed the professional corporations through which licensed practice could occur in states requiring PC structures.

That reciprocal dependence is not inherently unlawful.

It does, however, explain why the PC–MSO relationship is economically central rather than incidental.

The same governance record also justifies deeper control review#

Other facts justify investigation rather than a presumption of independence:

• The original MSA was signed by the same CEO on both sides.

• H.I.G. was included in the MSA notice architecture from inception.

• The manager may attend and participate in CFMG governance meetings.

• Company action can be concentrated through a single Company Designee.

• The 2019 assignment transferred stock-transfer restriction agreements into the Wellpath management structure.

• Bazzel came from the pre-merger CCS executive structure.

• Medrano simultaneously holds Wellpath regional medical and CFMG corporate roles.

• CFMG's principal office migrated from California to Wellpath's Tennessee corporate infrastructure.

• Current officers/directors use the same Tennessee administrative locus.

• Current shareholders remain undisclosed in the public evidence.

• The actual stock-succession rules remain missing.

Again, those facts do not establish illegality.

They identify the precise governance records needed to answer the question.

The current medical board guidance reinforces the control analysis#

The Medical Board’s current practice guidance says the corporate-practice doctrine is intended to prevent unlicensed persons from interfering with or influencing physician professional judgment.

The Board identifies physician-controlled functions that include:

• diagnostic testing;

• referrals;

• treatment;

• patient volume;

• physician working hours;

• medical-record control;

• clinically related hiring/firing;

• third-party payer parameters;

• coding and billing;

• medical equipment and supplies.

The Board expressly says these decisions cannot be delegated to an unlicensed person or management-services organization, although physicians may consult with management.

Primary source:

https://www.mbc.ca.gov/Licensing/Physicians-and-Surgeons/Practice-Information/

This current guidance matters to the stock-transfer analysis because formal authority over those decisions means little if a lay enterprise can simply replace the physician who exercises the authority.

Thus ownership control can become indirect clinical control .

The “affiliated physician” language needs careful analysis#

Wellpath’s bankruptcy filings describe PC owners as licensed physicians “affiliated with” the Debtors.

That phrase is important but ambiguous.

“Affiliated” could describe:

• employment;

• consulting;

• board role;

• management role;

• shared business relationship;

• other contractual connection.

It does not necessarily mean:

• Wellpath shareholder;

• controlled person;

• employee.

For each CFMG shareholder, the record should identify the exact form of affiliation.

If the physician owner simultaneously depends on Wellpath for:

• employment;

• compensation;

• benefits;

• officer title;

• stock eligibility,

the combined leverage may be greater.

If the physician owner has independent professional/economic standing, the governance picture may differ.

Current working thesis#

CFMG appears to be a real, legally distinct California professional corporation embedded within an exceptionally comprehensive Wellpath management architecture. Formal physician governance, county contracting, nondebtor status, and evidence of professional functions weigh against a simplistic shell-company theory. At the same time, Wellpath’s documented role reaches deeply into physician employment architecture, compensation, staffing, utilization management, records, finance, insurance, contracting, defense, and the succession machinery surrounding the professional-corporation model. The central unresolved question is not whether Wellpath owns CFMG stock—the current evidence does not establish that—but whether contractual and practical rights give the management enterprise power over who may own/control CFMG or over decisions California reserves to physicians.

IV. Contrary Evidence, Limits, and Competing Explanations#

A disciplined analysis must begin its limiting case with the strongest contrary evidence: The central limitation is the missing shareholder/stock-transfer record. Physician corporate titles are genuine governance evidence but are not proof of ownership or independence under disagreement.

DHEERAJ TARANATH is distinct from THE VERIFIED CFMG BOARD#

Dr. Dheeraj Taranath is highly relevant to CFMG operations, but the current evidence does not establish him as a CFMG shareholder, director, or officer.

Wellpath's current leadership page identifies him as:

Chief Clinical Officer, Wellpath

The Wellpath bankruptcy plan likewise listed him among the officers of reorganized Wellpath as Chief Clinical Officer.

County materials in 2026 identify him as a Wellpath chief medical/clinical executive.

He has also communicated on CFMG-related matters.

But those facts do not put him on CFMG's board.

This distinction is important because loose shorthand of the form "physician shareholders and leadership" is easy to apply to any senior clinician associated with the enterprise, including Taranath.

For public publication, that shorthand must not become a factual assertion of share ownership.

The correct description is:

Wellpath Chief Clinical Officer who has participated in CFMG-related clinical/organizational matters; no current public proof of CFMG share ownership or board office identified.

V. Missing Documents and Falsification Tests#

The record remains incomplete in material respects. Key unresolved points include the actual shareholder ledger, stock-transfer agreement, succession minutes, and the explanation for contradictory parent/subsidiary/affiliate filings.

Layer eight: medical records and information systems#

The manager’s role includes information technology, databases, connectivity, electronic medical-record implementation and maintenance, and supervision of record-maintenance infrastructure.

Those provisions establish broad technical and administrative access.

They do not establish that the manager could determine the substantive contents of a physician’s medical record.

That distinction matters because the Medical Board of California treats control of medical records as a professional-control issue.

For later investigation, every records question should be divided into:

• system ownership;

• technical administration;

• custodial responsibility;

• access control;

• content control;

• clinical amendment authority;

• disclosure authority.

A single word — “records” — is too imprecise.

The bankruptcy did not reorganize CFMG stock through the debtor plan#

Because CFMG was a nondebtor professional corporation, the Wellpath Chapter 11 did not simply convert CFMG stock into lender equity in the manner that debtor-company equity was restructured.

That distinction matters.

Wellpath itself announced in May 2025 that ownership of the reorganized Wellpath enterprise transitioned to a group of current and former lenders.

Public SEC filings by Prospect Capital show that its Wellpath debt was converted into debt and equity positions in New WPCC Parent, LLC . Prospect subsequently reported holdings including Series A Preferred Interests and Class A Common Interests in New WPCC Parent.

Those records illuminate the new ownership of the management enterprise.

They do not establish that New WPCC Parent owns CFMG's physician stock.

The more precise question is:

What happened to the MSA, stock-transfer restrictions, management rights, security interests, and succession mechanisms when the Wellpath management enterprise changed ownership?

That is the post-bankruptcy continuity issue.

The documents that now matter most#

Tier One:

• Every stock-transfer restriction agreement referenced in the 2019 assignment.

• Current CFMG stock ledger.

• Current shareholder agreement.

• Shareholder succession agreements.

• Options, proxies, nominee agreements, powers of attorney.

• CFMG bylaws.

• Company Designee appointments.

• Full Deficit Funding Loan Agreement and amendments.

• UCC-1 financing statements and continuations/terminations.

• Current security agreements.

• Bank signature cards.

• ACH and treasury authorities.

• Deposit-account control agreements.

• 2012 Credit Agreement and successor/refinancing agreements.

• Every MSA amendment since 2012.

• Post-bankruptcy ratification/assumption documents.

• 2025–2026 CFMG board/shareholder minutes.

• Monthly management-company bonus resolutions.

• Management-fee/FMV analyses.

• Current New WPCC Parent capitalization and governance agreements.

Tier Two:

• Intercompany ledgers.

• CFMG general ledger.

• Wellpath management-fee invoices.

• Deficit-funding advance history.

• Insurance/claims agreements.

• IT/data exit provisions.

• county change-of-MSO approval provisions.

• employment/personnel transition restrictions.

• Local Government–California delegation matrix.

• documents showing whether CFMG considered alternative managers during bankruptcy.

Shareholder#

The shareholder owns the professional corporation's stock.

Because CFMG is a California professional medical corporation, stock ownership is subject to California professional-corporation restrictions.

A shareholder's identity must be established through:

• stock ledger;

• stock certificate;

• shareholder agreement;

• transfer record;

• corporate minutes;

• authenticated corporate filing or admission.

A title alone is insufficient.

The current shareholder question remains unanswered#

This is perhaps the most important conclusion of the prior analysis.

The January and November 2025 California Statements of Information tell us:

• officers;

• directors;

• addresses.

They do not tell us:

• shareholders;

• share percentages;

• stock certificates;

• beneficial ownership;

• succession rights.

Wellpath has publicly described CFMG as physician-owned.

Kip Hallman publicly described it as owned primarily by a group of physicians and said there was no ownership overlap with Wellpath.

Those are meaningful corporate statements.

But the actual ownership schedule has not yet been obtained.

Accordingly, the record should not publish:

• "Bazzel owns CFMG";

• "Bazzel, Medrano and Kennedy are the shareholders";

• "Taranath is a CFMG shareholder";

• "Wellpath owns CFMG";

• "H.I.G. owns CFMG stock."

None of those propositions is currently established by sufficiently reliable primary evidence.

The stock-transfer restrictions could explain the succession pattern — but the documents are missing#

The 2019 assignment's express reference to "relevant stock transfer restriction agreements" becomes more important when placed beside the officer succession.

At least three major physician-leadership transitions occurred:

• Fithian era → Herr era;

• Herr era → transitional O'Bryan/Bazzel period;

• Bazzel era → current three-director board.

The unresolved question is whether any of these officer transitions coincided with stock succession.

Questions:

• Did Fithian sell or transfer shares?

• Did Herr acquire shares?

• Did Bazzel acquire shares?

• Were Medrano or Kennedy issued shares?

• Was a single physician shareholder replaced while board offices changed around that person?

• Did Wellpath or its predecessor have contractual approval over the transferee?

• Was stock held subject to a transfer restriction favoring the MSO?

• Did a physician's employment status affect ownership?

Those questions cannot be answered from public officer titles.

The stock documents are necessary.

THE WELLPath CFMG / CFMG HOLDINGS ENTITY MAY HELP EXPLAIN HISTORICAL CONFUSION ABOUT "PARENT" STATUS#

The discovery that Wellpath CFMG, Inc. was formerly CFMG Holdings Corp. provides a new interpretive clue.

Federal and other records have at times used descriptions such as:

• CFMG parent;

• CFMG subsidiary;

• CFMG affiliate;

• CMGC parent.

Some of those descriptions may reflect genuine relationships.

Some may reflect shorthand.

And some may be complicated by the coexistence of:

• the professional corporation;

• CFMG Holdings Corp.;

• Correctional Medical Group Companies;

• Wellpath CFMG, Inc.;

• Wellpath Management.

This is especially important for the unresolved Rule 7.1 corporate-disclosure anomaly identified in the prior analysis.

The correct next step is not to infer that the disclosures are wrong.

It is to retrieve the exact filed forms and identify which legal CFMG entity the disclosure actually names .

The naming collision is a plausible source of confusion, but that remains an inference until the filings are reviewed.

The central refinement to the current governance narrative#

Older shorthand:

"Bazzel, Medrano, Kennedy and Taranath are CFMG physician shareholders."

Better:

California Secretary of State records verify Bazzel, Medrano and Kennedy as CFMG officers and directors in 2025. Public records verify Taranath as Wellpath's Chief Clinical Officer. The current public evidence does not identify CFMG's shareholder roster or establish Taranath as a shareholder.

That distinction should be locked into future drafts.

Primary documents now required to complete the ownership chain#

The next document-production/retrieval priority is:

• CFMG stock ledger from 2012 to present.

• Every issued/cancelled stock certificate.

• Shareholder roster by year.

• Share percentages.

• CFMG shareholder agreements.

• Stock-transfer restriction agreements referenced in 2019 assignment.

• Buy-sell agreements.

• succession agreements.

• options.

• proxies.

• nominee/custodial agreements.

• death/disability succession provisions.

• license-loss succession provisions.

• employment-linked stock provisions.

• retirement/resignation transfers.

• board approvals of every stock transfer.

• shareholder approvals.

• valuations/purchase-price records.

• source of funds for each transfer.

• any MSO consent/veto rights.

• any security interest involving shares.

• all Company Designee appointments.

• bylaws from 2012 to present.

• articles/amendments.

• Statements of Information for every year available.

• board/director minutes.

• shareholder meeting minutes.

• written consents.

• conflict-of-interest policies.

• 2012 MSA approval resolutions.

• 2019 assignment approval resolutions.

• post-bankruptcy MSA ratification/continuation resolutions.

• 2026 Local Government–California authorization records.

The missing CFMG board record should not be treated as evidence of absence#

Because CFMG was a nondebtor, its ordinary board minutes would normally remain private corporate records.

A bankruptcy court generally does not require every nondebtor counterparty to publish internal deliberations merely because its contract partner files Chapter 11.

Therefore:

No public CFMG board minutes found ≠ no CFMG board deliberation occurred.

But where the substantive question is physician independence, those records become the best direct evidence.

The public record should therefore say:

No publicly filed CFMG board record has yet been identified showing how its physicians evaluated the manager’s bankruptcy and ownership transition.

That is accurate and neutral.

Why third-party descriptions of Wellpath owning CFMG carry limited weight#

Some county, media, labor, plaintiff, and advocacy materials describe CFMG as:

• owned by Wellpath;

• acquired by Wellpath;

• absorbed into Wellpath;

• formerly CFMG.

These statements are useful evidence of public operational identity and confusion.

They are weak evidence of actual stock ownership when contradicted by:

• CFMG professional-corporation status;

• bankruptcy treatment;

• Wellpath physician-ownership representations;

• Hallman’s no-overlap statement.

The Lake County Grand Jury’s statement that CFMG is owned by Wellpath is a useful example.

It is an official local-government report and therefore meaningful evidence of what County oversight personnel understood.

But it is not a stock ledger.

The public record should label such descriptions:

governmental-client characterization, not independently verified corporate ownership.

Specific document request language#

A targeted request should seek:

All stock transfer agreements, stock transfer restriction agreements, shareholder succession agreements, continuity agreements, assignable options, stock powers, proxies, powers of attorney, nominee agreements, escrow agreements, buy-sell agreements, and related amendments concerning any shares of California Forensic Medical Group, Incorporated, including all agreements assigned or referenced in the January 1, 2019 Assignment of Management Services Agreement.

It should also request:

All documents identifying any person or entity with authority to nominate, approve, reject, remove, replace, or designate a CFMG shareholder, director, officer, Chief Executive Officer, or Company Designee.

That language is considerably more precise than requesting “ownership records” generically.

A reported physician decision does not, by itself, complete the decision chain#

A governance question can be posed publicly without any private record: if a future public filing, deposition or produced document shows physician participation in a specific personnel decision, that would be direct evidence of professional governance in operation. Until then the question stays open.

The same sequence applies to any public decision event through the same sequence used elsewhere in the series: origin → recommendation → authorized professional review → approval or veto → implementation . A later physician ratification is not the same as an originating decision; a management recommendation is not the same as final authority; and mere alignment does not reveal who would prevail under disagreement.

The highest-value evidence is a conflict-tested record showing that an authorized CFMG physician body could say no and that the enterprise was required to follow its decision—or the reverse. Until such a public record is available, private personnel material should remain a research lead rather than a published merits proposition.

Conclusion#

A public attorney-facing formulation can state:

California litigation does not support the proposition that CFMG simply became Wellpath, nor does it support treating the two organizations as operational strangers. Post-bankruptcy cases repeatedly confirm that CFMG remained a separate professional corporation and non-debtor entity, while earlier and contemporaneous litigation also documents substantial operational integration. In \_Smith\_, CFMG accepted a case-specific stipulation treating CFMG and Wellpath as the same entity for all intents and purposes, and the court later held CFMG to that position. In \_D.M.\_, the discovery record reflects a representation that the entities were effectively the same with respect to records, employees, and other functions. By contrast, \_Pugh\_, \_J.S.\_, \_Reynolds\_, and \_Hernandez\_ document the juridical distinction that became critical after Wellpath's bankruptcy. \_Overfield\_ adds sworn physician-employment evidence: CFMG's corporate witness was a Wellpath HR executive who testified both that CFMG paid its employees and Wellpath supplied HR support, and that a CFMG physician was terminated by management working for Wellpath. The same witness denied that the termination involved the physician's clinical judgment. Taken together, the cases establish separateness and integration simultaneously. They do not yet resolve who possessed final authority when administration crossed into physician-reserved professional decisions.

That is the correct litigation synthesis at this stage.

Permanent wording / correction rules#

• Never conflate California Forensic Medical Group, Incorporated with Wellpath CFMG, Inc. f/k/a CFMG Holdings Corp.

• Never call Bazzel, Medrano, Kennedy, Taranath, Herr, Fithian, or another physician a CFMG shareholder without stock evidence.

• Do not state that H.I.G. directly purchased CFMG professional-corporation stock absent acquisition/stock records.

• Do not treat Wellpath bankruptcy language referring to “ownership interests” as an admission that Wellpath owned CFMG stock.

• Do not say the 2025 Plan assigned the CFMG MSA “to the lenders.” Current best reconstruction is continued Wellpath LLC counterparty + Plan assumption/revesting + new upstream ownership.

• Treat Art Center and Carbon Health as California legal/enforcement comparators, not adjudications against CFMG.

• Treat county phrases such as “CFMG/Wellpath,” “now Wellpath,” and “dba Wellpath” as evidence of client/public understanding, not dispositive corporate genealogy.

• Treat \*Smith\*’s same-entity stipulation as binding in that case, not universal merger/alter-ego proof.

• Treat Reynolds , Johnson , Pugh , J.S. , Yang , and similar post-bankruptcy corrections as strong entity-separateness evidence.

• Treat Rule 30(b)(6) use of a Wellpath employee as institutional-knowledge evidence, not automatic alter ego.

• Always distinguish participation , recommendation , approval , veto , implementation , and blocking power .

Tier-one open evidence#

The highest-value missing items remain:

• CFMG-specific stock-transfer restriction / succession agreement.

• CFMG stock ledger and shareholder roster by year.

• CFMG bylaws and Company-Designee appointments.

• Proxy, option, stock-power, escrow, nominee, or power-of-attorney instruments.

• Docket 194 CFMG assumption/cure row and proposed cure amount.

• CFMG board/shareholder minutes from the bankruptcy and emergence period.

• Deficit Funding Loan Agreement.

• UCC/security-interest records.

• Cash/bank signature and treasury authorities.

• Monthly CFMG management-bonus resolutions.

• Smith ECF 156 and full financial-discovery record.

• Full Overfield Chapman termination file/approval chain.

• Utilization-management denial/appeal/override records.

• Current Local Government–California delegation matrix.

• Post-emergence MSA/stock-instrument amendments or reaffirmations.

VI. Why the Issue Matters#

The stakes are practical rather than semantic. Counties need to know which entity is accountable for contracted performance; clinicians need to know where professional authority resides; courts and regulators need entity-specific evidence rather than brand shorthand; and the public needs a record that distinguishes corporate continuity from operational integration. Those distinctions become most important when the actors disagree, when a contract changes hands, when a professional decision conflicts with an economic preference, or when litigation requires a precise answer to who had authority to act.

Clinical policy — enterprise standardization is not automatically unlawful#

National healthcare organizations commonly maintain enterprise policies.

A Wellpath policy appearing in a California jail does not, by itself, prove that Wellpath practiced medicine. The relevant questions are:

• Who authored the policy?

• Was it administrative or clinical?

• Did CFMG physician leadership review it before California implementation?

• Could CFMG modify it?

• Could a site physician depart from it based on patient-specific judgment?

• Who adjudicated exceptions?

• Who could discipline a physician for deviation?

• Who controlled version history?

• What happened when CFMG and Wellpath disagreed?

The strongest evidence of lawful independence would be a record showing CFMG physicians refusing, modifying, or conditioning a Wellpath clinical policy before implementation in California.

The strongest evidence pointing in the opposite direction would be a record showing a Wellpath enterprise policy imposed on CFMG physicians over a contrary physician-governance decision.

Until such records are obtained, “Wellpath policy” should be treated as evidence of infrastructure and standardization—not as dispositive evidence of unlawful control.

VII. Falsification Tests and Evidentiary Limits Note#

The record does not support be read as establishing an unproven motive, an undisclosed shareholder, an unlawful medical override, or a legal conclusion that a court or regulator has not made. The strongest version of the thesis is the one that survives the missing-document test: identify the instrument, minutes, ledger, delegation, approval record, or disagreement event that would materially change the conclusion, then state what has and has not been found. If later primary evidence contradicts a proposition stated here, the correction should be made at the proposition level rather than defended through branding or organizational shorthand.

VIII. Related Articles#

• Article 025 — Scott Kennedy and the Financial Side of Physician Governance

• Article 027 — Officer Is Not Owner: The Most Important Corporate-Governance Correction in the Record

• Article 024 — Richard Medrano: One Physician, Two Institutional Roles

The proposition to be tested#

The central proposition in this article is not that every appearance of the Wellpath name proves control, nor that formal CFMG separateness ends the inquiry. The proposition to be tested is narrower: What is the difference between Wellpath's Chief Clinical Officer and CFMG's professional-corporation authority? A serious legal brief should state that proposition before discussing motive, liability, or remedy because the same document can be highly probative on one dimension and nearly irrelevant on another.

For this subject, the principal evidentiary dimensions are enterprise clinical leadership, professional-corporation authority, policy influence, and role separation. The source spine identified in the current public record is: Wellpath leadership page; prior local-government medical role; current program-development language; no verified CFMG board/shareholder status. Those sources should not be pooled as though they were interchangeable. A county contract speaks most reliably to the county's counterparty and purchased obligations. A management agreement speaks to contractual allocation between the professional corporation and manager. A court order speaks to the matter actually adjudicated. A party filing or corporate announcement remains a representation unless independently adopted or found by a tribunal.

Governance evidence must distinguish office, employment, management title, board membership, shareholder status, delegated authority, and signature authority. These categories can overlap in one person without becoming legally interchangeable. The relevant capacity must be identified for each act. The practical advantage of that method is that it prevents a common failure in complex-enterprise investigations: using a true fact about one relationship as proof of a different relationship. A shared brand may show integration; a W-2 may show payroll identity; a contract signature may show authority to bind a corporation; an officer title may show corporate office. None automatically proves stock ownership or final clinical authority.

The charging or enforcement threshold, if any regulator ever considered one, would therefore require an evidence chain rather than a collage: identify the protected or regulated function; identify the actor with formal authority; reconstruct the first operative decision; identify the person or entity that could approve, reject, modify, or reverse it; and verify who implemented the result. Until that chain is complete, the proper classification is evidence, inference, or unresolved question—not adjudicated fact.

Weighing the evidence#

The evidentiary hierarchy for Dheeraj Taranath and the Enterprise Clinical Layer should begin with contemporaneous primary instruments and end with retrospective shorthand. Executed contracts, amendments, assignments, board resolutions, authenticated corporate records, court orders, government payroll or labor records, and formal agency records ordinarily deserve more weight on the proposition they were created to establish than marketing language or later summaries. Even among primary materials, however, purpose matters. A contract can establish contractual rights without proving that those rights were exercised; a tax record can establish reporting without deciding every common-law employer factor; a bankruptcy schedule can establish debtor treatment without answering professional-governance questions for a nondebtor corporation.

The article's existing record illustrates why that hierarchy matters.ithin its evidentiary lane. The governing question is narrow: What is the difference between Wellpath's Chief Clinical Officer and CFMG's professional-corporation authority? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

A prosecutor, defense lawyer, regulator, or investigative editor should ask five questions of every source: Who created it? What legal or business purpose did it serve? What date and entity does it concern? Is the statement a recital, operative term, allegation, stipulation, finding, or marketing representation? What independent record could confirm or contradict it? Applying those questions consistently is more valuable than multiplying citations that all derive from the same underlying assertion.

This also defines how contradictions should be handled. When two records use different labels, the first step is not to accuse one of being false. The first step is to determine whether the records were answering different questions. Only after normalizing entity, date, capacity, forum, and purpose should a remaining contradiction be treated as substantive. That discipline makes the article stronger for both sides because it identifies where the record genuinely conflicts and where the conflict is merely semantic.

Chronology as a control test#

Chronology is often more probative than organizational charts. The decisive question is not merely who possessed authority on paper, but when a decision became operative and what happened immediately before and after that moment. A later board vote, HR notice, county communication, or litigation position may confirm, ratify, or explain an earlier act without proving who made the initial decision. Conversely, an early recommendation may have no legal effect until the authorized professional or contracting entity adopts it.

For Dheeraj Taranath and the Enterprise Clinical Layer, the chronology should be reconstructed with document-level precision. Investigators should place each significant contract, amendment, email that has entered the public record, board action, personnel or agency event that is lawfully publishable, and court filing on a single timeline. Each entry should identify the actor, capacity, entity, action verb, and legal effect. Terms such as “recommended,” “approved,” “directed,” “implemented,” “ratified,” “reported,” and “terminated” are not synonyms. The wording can reveal whether a participant supplied information, exercised discretion, or merely carried out another actor's decision.

The current article supplies anchor points that should remain central. What happened to the CFMG shareholder, board, and Company Designee structure during the 2018–2019 Wellpath transition while Herr was president? Several federal cases include corporate-disclosure entries describing CFMG and Wellpath through “affiliate,” “other affiliate,” or more expansive relationship labels.

A robust chronology is also the best protection against overstatement. If the alleged controlling act occurred before the supposedly controlling actor entered the process, that theory weakens. If a professional body acted only after implementation, a claim that it supplied the first operative decision requires qualification. If the public record shows independent deliberation before implementation, that evidence materially strengthens the formal-independence account. The analysis therefore must treat time as an evidentiary variable, not just background narrative.

The strongest lawful explanation and the strongest investigative hypothesis#

A publication written to withstand adversarial review should state the strongest lawful explanation in full rather than burying it. The strongest conventional explanation is that physician executives can hold enterprise and professional-corporation roles precisely because integrated healthcare organizations need clinical leaders who can communicate across corporate boundaries. Dual titles do not establish that corporate formalities were ignored. That explanation is not a concession; it is the baseline against which any more serious inference must be tested.

The strongest investigative hypothesis must be equally disciplined. The strongest investigative hypothesis is that succession, appointment, or economic dependence may have reduced the practical independence suggested by formal physician titles. That theory requires the missing governance records—bylaws, minutes, share ledgers, transfer restrictions, appointment resolutions, and conflict-tested decisions. The hypothesis should not be written as a conclusion unless the missing bridge evidence exists. Its value is to identify the next records and witnesses that matter.

The two accounts can coexist over large portions of the record. An enterprise can be operationally integrated and legally segmented. A physician professional corporation can be genuine while depending heavily on an MSO. An MSO can provide extensive infrastructure while a physician body retains clinical authority. A county can demand staffing and quality metrics while individual clinicians retain professional duties. The legal issue arises at the boundary: who had the lawful and practical ability to decide the disputed function when interests diverged?

The analysis must resist labels such as “shell,” “alter ego,” “subsidiary,” “employer,” or “controller” unless the source and legal test support them. The more defensible phrasing is functional and dated: the record shows that a specified entity administered payroll, signed a county amendment, sponsored a benefit, chaired a committee, received a claim, or approved a clinical policy. From those proven verbs, the investigation can build—but should not skip—the legal analysis.

Cross-examination map and missing documents#

If the subject of this article were tested through sworn testimony, the most useful examination would be document-led. Begin by authenticating the governing instrument and confirming the witness's capacity. Then ask who had authority to initiate the process, who prepared the recommendation, who received the supporting packet, who could request additional information, who could reject or modify the proposal, who communicated the final decision, and who controlled implementation. Where the witness answers “Wellpath,” “CFMG,” “the County,” “HR,” or “the physician board,” the next question should be: which legal entity, which office, and under what written authority?

For Dheeraj Taranath and the Enterprise Clinical Layer, the highest-value document requests follow directly from the core question. They include the operative version of any agreement discussed in the article; amendments and assignment instruments; contemporaneous board or committee minutes; delegation matrices; signature-authority resolutions; organizational charts that identify legal entities rather than brands; policies showing approval history; relevant contract exhibits; and any nonprivileged communications that record an actual disagreement or override. Where ownership or succession is material, shareholder ledgers, stock certificates, transfer restrictions, and appointment resolutions outrank biographies or titles. Where employment is material, offer letters, W-2/payroll records, handbooks, benefit participation records, HR delegations, and termination authority should be separated by function.

The witness examination should also test the absence of evidence. If no example can be identified in which the professional corporation rejected a management recommendation on a physician-reserved issue, that absence is relevant but not dispositive; disagreement may be rare or resolved informally. Conversely, if multiple authenticated examples show independent professional rejection followed by implementation of the physician decision, that is powerful counterevidence to a practical-control thesis. The proper question is not whether a document can be imagined, but whether the governance structure leaves an observable record when authority is actually exercised.

Finally, testimony should distinguish institutional practice from a witness's personal understanding. A senior executive may accurately describe how the enterprise usually operates without knowing the legal ownership of every professional corporation. A county official may accurately describe the contractor without knowing internal delegation. A physician officer may know clinical governance but not bankruptcy treatment. Capacity-specific testimony prevents one witness from being treated as omniscient.

How each source is used#

The following public authorities are tied to defined propositions in this article. They are not interchangeable: each is cited for the institutional purpose it can actually prove, and none is treated as a universal finding about ownership, employment, liability, or professional control.

• Wellpath, 'Wellpath Announces Creation of a New Operating Division in California,' Mar. 13, 2026. Used here as Wellpath's current public description of its California operating layer and its relationship with CFMG.
• Medical Board of California, Practice Information / Corporate Practice of Medicine guidance. Used here as California regulator guidance identifying physician-reserved decisions and limits on delegation of professional judgment to management organizations.
• California Business and Professions Code § 2400. Used here as the statutory anchor for California's prohibition on the unlicensed corporate practice of medicine.
• California Attorney General, Apr. 1, 2026, amicus announcement defending California's corporate-practice-of-medicine prohibition in Art Center Holdings. Used here as a current California enforcement position emphasizing rights of control over professional functions, not merely formal labels.
• 2012 CFMG Management Services Agreement — California Forensic Medical Group, Incorporated and California Forensic Management Group, Inc., Dec. 31, 2012. Used here as operative baseline for the allocation of management functions, physician-reserved responsibilities, and the manager/professional-corporation relationship.
• Overfield v. Wellpath Community Care, LLC et al., E.D. Cal. No. 2:24-cv-00199-TLN-AC, ECF No. 87 (Aug. 11, 2026). Used here as a public discovery order concerning organizational testimony and a CFMG physician termination, useful for tracing employment authority without treating the procedural ruling as a merits adjudication.
• Johnson v. County of Alameda, N.D. Cal. No. 3:23-cv-04069, ECF No. 76 (Mar. 2026). Used here as a public litigation correction distinguishing CFMG from Wellpath Management, Inc. and the debtor-side entities.

Sources and authorities#

1. Wellpath, 'Wellpath Announces Creation of a New Operating Division in California,' Mar. 13, 2026 — https://wellpathcare.com/2026/03/13/wellpath-announces-creation-of-a-new-operating-division-in-california-appoints-new-highly-experienced-leader/
2. Medical Board of California, Practice Information / Corporate Practice of Medicine guidance — https://www.mbc.ca.gov/Licensing/Physicians-and-Surgeons/Practice-Information/
3. California Business and Professions Code § 2400 — https://leginfo.legislature.ca.gov/faces/codes\_displaySection.xhtml?lawCode=BPC&sectionNum=2400.
4. California Attorney General, Apr. 1, 2026, amicus announcement defending California's corporate-practice-of-medicine prohibition in Art Center Holdings — https://oag.ca.gov/news/press-releases/attorney-general-bonta-files-amicus-brief-defense-california%E2%80%99s-ban-corporate
5. 2012 CFMG Management Services Agreement — California Forensic Medical Group, Incorporated and California Forensic Management Group, Inc., Dec. 31, 2012 — https://www.prisonlegalnews.org/news/publications/california-forensic-medical-group-incorporated-management-services-agreement/
6. Overfield v. Wellpath Community Care, LLC et al., E.D. Cal. No. 2:24-cv-00199-TLN-AC, ECF No. 87 (Aug. 11, 2026)
7. Johnson v. County of Alameda, N.D. Cal. No. 3:23-cv-04069, ECF No. 76 (Mar. 2026) — https://docs.justia.com/cases/federal/district-courts/california/candce/3%3A2023cv04069/416712/76

Citation rule: These sources support only the propositions identified in the article and source analysis. A party filing remains a party position unless adopted by a court; a corporate announcement remains a corporate representation; a contract proves allocated rights but not necessarily implementation; and a regulator's guidance or enforcement position is not an adjudication against CFMG unless a cited matter says so.